Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease ContinuumAndréa Lessa Benedet, Alyssa Stevensson, Natàlia Vilor‐Tejedor et al.|JAMA Neurology|2021Cited by 627
Biomarker modeling of Alzheimer’s disease using PET-based Braak stagingJoseph Therriault, Pedro Rosa‐Neto, Tharick A. Pascoal et al.|Nature Aging|2022Cited by 300
Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission TomographyJoseph Therriault, Pedro Rosa‐Neto, Marie Vermeiren et al.|JAMA Neurology|2022Cited by 261
Comparing tau status determined via plasma pTau181, pTau231 and [18F]MK6240 tau-PETCécile Tissot, Pedro Rosa‐Neto, Joseph Therriault et al.|EBioMedicine|2022Cited by 76
CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individualsJoel Simrén, Kaj Blennow, Wagner S. Brum et al.|Alzheimer s Research & Therapy|2022Cited by 33